<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088760</url>
  </required_header>
  <id_info>
    <org_study_id>2018-8568</org_study_id>
    <nct_id>NCT04088760</nct_id>
  </id_info>
  <brief_title>TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders</brief_title>
  <official_title>Safety and Efficacy of TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders in Children and Adolescent/Young Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted
      allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant
      disorders in children and adolescent/young adult patients using the CliniMACS® immunomagnetic
      selection device (Miltenyi Biotec).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute graft versus host disease (GVHD) remains a significant cause of morbidity and mortality
      and is the biggest barrier to successful allogeneic hematopoietic cell transplantation (HSCT)
      outcomes. Improved methods of acute GVHD prevention are needed. TCRαβ+/CD19+ depletion of
      allogeneic hematopoietic stem cell products offers an opportunity to limit the risk of acute
      GVHD by removing TCRαβ+ T cells and CD19+ B cells which participate in acute GVHD initiation
      and perpetuation. The purpose of this study is to investigate the safety and efficacy of
      TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for malignant and
      non-malignant disorders in children and adolescent/young adult patients using the CliniMACS®
      immunomagnetic selection device (Miltenyi Biotec).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of infusion-related reactions</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment and Sustained Donor Chimerism</measure>
    <time_frame>100 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Allogeneic Hematopoietic Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>TCRαβ+/CD19+ depleted HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)</intervention_name>
    <description>The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.</description>
    <arm_group_label>TCRαβ+/CD19+ depleted HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient being treated at Cincinnati Children's Hospital requiring an allogeneic
             HSCT who lacks an HLA-genotypically matched related donor.

        Exclusion Criteria:

          -  Prior allogeneic transplant with active acute or chronic GVHD, or life-threatening
             infection. Patients with a prior history of allogenic transplant without active GVHD
             or life-threatening infection can be considered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly McIntosh</last_name>
    <phone>513-803-0460</phone>
    <email>kelly.mcintosh@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celeste Dourson</last_name>
    <phone>513-636-7679</phone>
    <email>Celeste.Dourson@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly McIntosh</last_name>
      <phone>513-803-0460</phone>
      <email>Kelly.McIntosh@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Celeste Dourson</last_name>
      <phone>513-636-7679</phone>
      <email>Celeste.Dourson@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Parinda Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Marsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

